Do Vancomycin Pharmacokinetics Differ Between Obese and Non-obese Patients? Comparison of a General-Purpose and Four Obesity-Specific Pharmacokinetic Models

Over the past decade, numerous obesity-specific pharmacokinetic (PK) models and dosage regimens have been developed. However, it is unclear whether vancomycin PKs differ between obese and other patients after accounting for weight, age, and kidney function. In this study, the authors investigated wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Colin, Pieter J., Eleveld, Douglas J., Hart, Andrew, Thomson, Alison H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Therapeutic Drug Monitoring 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803436/
https://www.ncbi.nlm.nih.gov/pubmed/33278242
http://dx.doi.org/10.1097/FTD.0000000000000832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803436/
https://www.ncbi.nlm.nih.gov/pubmed/33278242
http://dx.doi.org/10.1097/FTD.0000000000000832

Ejemplares similares